Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli : Results From a Nationwide Study in Italy (ALARICO Network)
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Our aim was to analyze mortality attributable to carbapenem-resistant (CR) gram-negative bacilli (GNB) in patients with bloodstream infections (BSIs).
METHODS: Prospective multicentric study including patients with GNB-BSI from 19 Italian hospitals (June 2018-January 2020). Patients were followed-up to 30 days. Primary outcomes were 30-day mortality and attributable mortality. Attributable mortality was calculated in the following groups: Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales, metallo-β-lactamases (MBL)-producing Enterobacterales, CR-Pseudomonas aeruginosa (CRPA), CR-Acinetobacter baumannii (CRAB). A multivariable analysis with hospital fixed-effect was built to identify factors associated with 30-day mortality. Adjusted OR (aORs) were reported. Attributable mortality was calculated according to the DRIVE-AB Consortium.
RESULTS: Overall, 1276 patients with monomicrobial GNB BSI were included: 723/1276 (56.7%) carbapenem-susceptible (CS)-GNB, 304/1276 (23.8%) KPC-, 77/1276 (6%) MBL-producing CRE, 61/1276 (4.8%) CRPA, and 111/1276 (8.7%) CRAB BSI. Thirty-day mortality in patients with CS-GNB BSI was 13.7% compared to 26.6%, 36.4%, 32.8% and 43.2% in patients with BSI by KPC-CRE, MBL-CRE, CRPA and CRAB, respectively (P < .001). On multivariable analysis, age, ward of hospitalization, SOFA score, and Charlson Index were factors associated with 30-day mortality, while urinary source of infection and early appropriate therapy resulted protective factors. Compared to CS-GNB, MBL-producing CRE (aOR 5.86, 95% CI 2.72-12.76), CRPA (aOR 1.99, 95% CI 1.48-5.95) and CRAB (aOR 2.65, 95% CI 1.52-4.61) were significantly associated with 30-day mortality. Attributable mortality rates were 5% for KPC-, 35% for MBL, 19% for CRPA, and 16% for CRAB.
CONCLUSIONS: In patients with BSIs, carbapenem-resistance is associated with an excess of mortality, with MBL-producing CRE carrying the highest risk of death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 12 vom: 16. Juni, Seite 2059-2069 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Acinetobacter baumannii |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 24.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad100 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353082783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353082783 | ||
| 003 | DE-627 | ||
| 005 | 20231226055205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad100 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM353082783 | ||
| 035 | |a (NLM)36801828 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Falcone, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli |b Results From a Nationwide Study in Italy (ALARICO Network) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Our aim was to analyze mortality attributable to carbapenem-resistant (CR) gram-negative bacilli (GNB) in patients with bloodstream infections (BSIs) | ||
| 520 | |a METHODS: Prospective multicentric study including patients with GNB-BSI from 19 Italian hospitals (June 2018-January 2020). Patients were followed-up to 30 days. Primary outcomes were 30-day mortality and attributable mortality. Attributable mortality was calculated in the following groups: Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales, metallo-β-lactamases (MBL)-producing Enterobacterales, CR-Pseudomonas aeruginosa (CRPA), CR-Acinetobacter baumannii (CRAB). A multivariable analysis with hospital fixed-effect was built to identify factors associated with 30-day mortality. Adjusted OR (aORs) were reported. Attributable mortality was calculated according to the DRIVE-AB Consortium | ||
| 520 | |a RESULTS: Overall, 1276 patients with monomicrobial GNB BSI were included: 723/1276 (56.7%) carbapenem-susceptible (CS)-GNB, 304/1276 (23.8%) KPC-, 77/1276 (6%) MBL-producing CRE, 61/1276 (4.8%) CRPA, and 111/1276 (8.7%) CRAB BSI. Thirty-day mortality in patients with CS-GNB BSI was 13.7% compared to 26.6%, 36.4%, 32.8% and 43.2% in patients with BSI by KPC-CRE, MBL-CRE, CRPA and CRAB, respectively (P < .001). On multivariable analysis, age, ward of hospitalization, SOFA score, and Charlson Index were factors associated with 30-day mortality, while urinary source of infection and early appropriate therapy resulted protective factors. Compared to CS-GNB, MBL-producing CRE (aOR 5.86, 95% CI 2.72-12.76), CRPA (aOR 1.99, 95% CI 1.48-5.95) and CRAB (aOR 2.65, 95% CI 1.52-4.61) were significantly associated with 30-day mortality. Attributable mortality rates were 5% for KPC-, 35% for MBL, 19% for CRPA, and 16% for CRAB | ||
| 520 | |a CONCLUSIONS: In patients with BSIs, carbapenem-resistance is associated with an excess of mortality, with MBL-producing CRE carrying the highest risk of death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acinetobacter baumannii | |
| 650 | 4 | |a Klebsiella pneumoniae | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a attributable mortality | |
| 650 | 4 | |a carbapenem resistance | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Tiseo, Giusy |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonara, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Marino, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Di Caprio, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Carretta, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Mularoni, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Mariani, Michele Fabiano |e verfasserin |4 aut | |
| 700 | 1 | |a Maraolo, Alberto Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Scotto, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Dalfino, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Corbo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Macera, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Medaglia, Alice Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a d'Errico, Maria Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Gioè, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Sgroi, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Del Vecchio, Rosa Fontana |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Albanese, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Buscemi, Calogero |e verfasserin |4 aut | |
| 700 | 1 | |a Talamanca, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Raponi, Giammarco |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Antonina |e verfasserin |4 aut | |
| 700 | 1 | |a Iacobello, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Corrao, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Morana, Uccio |e verfasserin |4 aut | |
| 700 | 1 | |a Pieralli, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Santantonio, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Cascio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Cacopardo, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Farcomeni, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Venditti, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Menichetti, Francesco |e verfasserin |4 aut | |
| 700 | 0 | |a Advancing knowLedge on Antimicrobial Resistant Infections Collaboration Network (ALARICO Network) |e verfasserin |4 aut | |
| 700 | 1 | |a Carpentieri, Maria Stella |e investigator |4 oth | |
| 700 | 1 | |a Sofia, Sonia |e investigator |4 oth | |
| 700 | 1 | |a Ferla, Lucia La |e investigator |4 oth | |
| 700 | 1 | |a Pietromatera, Grazia |e investigator |4 oth | |
| 700 | 1 | |a Palazzo, Donatella |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 12 vom: 16. Juni, Seite 2059-2069 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:12 |g day:16 |g month:06 |g pages:2059-2069 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad100 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 12 |b 16 |c 06 |h 2059-2069 | ||